Back to News & Events

GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trial

Share this
GLY-200, an oral pharmacologic duodenal exclusion drug article

Your development journey
starts with a conversation.

ProSciento
Privacy Overview

More information about our Privacy Policy can be found here.